A Long-Term, Open-Label Study Of CP-690,550 To Confirm The Safety Following Long Term Administration Of CP-690,550 In The Treatment Of Rheumatoid Arthritis.

Trial Profile

A Long-Term, Open-Label Study Of CP-690,550 To Confirm The Safety Following Long Term Administration Of CP-690,550 In The Treatment Of Rheumatoid Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2018 Results of pooled data from two open-label LTE studies (NCT00413699 [database lock: March 2017] and NCT00661661) presented at the 19th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2018 Results of pooled post-hoc analysis from two open-label extension studies including this study presented at the 19th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top